Outlook Therapeutics (OTLK) Preferred Stock Liabilities: 2017-2020
Historic Preferred Stock Liabilities for Outlook Therapeutics (OTLK) over the last 2 years, with Mar 2020 value amounting to $6.5 million.
- Outlook Therapeutics' Preferred Stock Liabilities rose 28.34% to $6.5 million in Q1 2020 from the same period last year, while for Mar 2020 it was $6.5 million, marking a year-over-year increase of 28.34%. This contributed to the annual value of $5.4 million for FY2019, which is 13.20% up from last year.
- Outlook Therapeutics' Preferred Stock Liabilities amounted to $6.5 million in Q1 2020, which was down 21.38% from $8.2 million recorded in Q4 2019.
- Outlook Therapeutics' Preferred Stock Liabilities' 5-year high stood at $18.3 million during Q1 2018, with a 5-year trough of $2.9 million in Q3 2017.
- Moreover, its 3-year median value for Preferred Stock Liabilities was $5.2 million (2019), whereas its average is $6.9 million.
- Within the past 5 years, the most significant YoY rise in Outlook Therapeutics' Preferred Stock Liabilities was 68.41% (2019), while the steepest drop was 72.46% (2019).
- Quarterly analysis of 4 years shows Outlook Therapeutics' Preferred Stock Liabilities stood at $17.2 million in 2017, then slumped by 71.58% to $4.9 million in 2018, then spiked by 68.41% to $8.2 million in 2019, then increased by 28.34% to $6.5 million in 2020.
- Its Preferred Stock Liabilities stands at $6.5 million for Q1 2020, versus $8.2 million for Q4 2019 and $5.4 million for Q3 2019.